Valsartan solid oral dosage forms and methods of making such formulations

Details for Australian Patent Application No. 2009219250 (hide)

Owner Novartis AG

Inventors Matharu, Amol; Wagner, Robert Frank; Taillardat, Agnes

Agent Davies Collison Cave

Pub. Number AU-A-2009219250

PCT Pub. Number WO2009/108824

Priority 61/032,187 28.02.08 US

Filing date 27 February 2009

Wipo publication date 3 September 2009

International Classifications

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

A61K 9/16 (2006.01) Medicinal preparations characterised by special physical form - Agglomerates

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 9/22 (2006.01) Medicinal preparations characterised by special physical form - Sustained or differential release type

Event Publications

19 August 2010 PCT application entered the National Phase

  PCT publication WO2009/108824 Priority application(s): WO2009/108824

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009219259-Diagnostic skin mapping by MRS, MRI and other methods

2009219246-Persistent device relationships in wagering game systems